SCHEMBL1158641

SCHEMBL1158641

Cc1ccnc(Nc2cc3cc[nH]c(=O)c3c(NCCc3cccnc3)n2)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KARS1 Q15046 6/20 0.42
INSR P06213 1/20 0.41
IGF1R P08069 1/20 0.41
FGFR1 P11362 1/20 0.41
KDR P35968 1/20 0.41
FER P16591 1/20 0.38
ZAP70 P43403 2/20 0.37
TYK2 P29597 1/20 0.36
PIK3CD O00329 1/20 0.36
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PTGDR Q13258 1/20 0.35
F2 P00734 1/20 0.35
JAK3 P52333 1/20 0.35
NOS2 P35228 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1158507 0.88 INSR (0.41) INSRIGF1RFGFR1KDRZAP70
SCHEMBL12848848 0.84 FER (0.40) KARS1IGF1RKDRFERZAP70
SCHEMBL1158580 0.83 NOS2 (0.52) KARS1IGF1RKDRFERZAP70
SCHEMBL1158729 0.83 KARS1 (0.49) KARS1IGF1RKDRFERZAP70
SCHEMBL1158364 0.82 KARS1 (0.42) KARS1IGF1RKDRFERZAP70
SCHEMBL1158652 0.82 FER (0.41) KARS1IGF1RKDRFERZAP70
SCHEMBL6524126 0.81 ATAD2 (0.48) KARS1IGF1RKDRFERZAP70
SCHEMBL1158622 0.81 KARS1 (0.43) KARS1IGF1RKDRFERZAP70
SCHEMBL1158220 0.81 FER (0.39) KARS1IGF1RKDRFERZAP70
SCHEMBL1158538 0.80 KARS1 (0.41) KARS1IGF1RKDRFERZAP70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP claimed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US claimed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO claimed
EP-2459556-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2012-06-06 EP disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-03-03 US disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed
WO-2011014515-A1 2, 7 -NAPHTHYRIDIN- 1 -ONE DERIVATIVES AS SYK KINASE INHIBITORS IRM LLC (BM) 2011-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110053897-A1 COMPOUNDS AND COMPOSITIONS AS SYK KINASE INHIBITORS SYK, BTK, LYN KARS1 2211/4885INSR 1184/4885IGF1R 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.